GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Margin of Safety % (DCF Dividends Based)

Apollon Formularies (AQSE:APOL) Margin of Safety % (DCF Dividends Based) : N/A (As of Jun. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Apollon Formularies's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.


Competitive Comparison of Apollon Formularies's Margin of Safety % (DCF Dividends Based)

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's Margin of Safety % (DCF Dividends Based) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Margin of Safety % (DCF Dividends Based) falls into.



Apollon Formularies Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

FPA Capital Fund Finds Only 2 Stocks Matching Their Criteria in Q1

By Holly LaFon Holly LaFon 04-10-2013

7 Arbitrage Trades With High Profit Potential

By Jonathan Poland Jonathan Poland 11-30-2016

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015

Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC

By Jimmy Xiao gurujx 05-17-2015

FPA Capital Fund Comments on Apollo Education Group

By Holly LaFon Holly LaFon 02-09-2016

The Yacktman Focused Fund's Top Growth Stocks

By Dianne Tordillo Dianne Tordillo 01-25-2013

Weekly Guru Bargains Highlights: APOL, GNW, BTU, NIHD, OKE

By GuruFocus GuruFocus 06-30-2012

FPA Capital Comments on Apollo Education

By Holly LaFon Holly LaFon 01-30-2017

FPA Capital Comments on Apollo

By Holly LaFon 07-29-2013

Valuing Donald Yacktman's Portfolio: The Peter Lynch Fair Value

By Holly LaFon Holly LaFon 07-02-2012